Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HYDROCHLORIDE vs DESFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Induction and maintenance of general anesthesia,Sedation,Analgesic for acute pain,Treatment-resistant depression (off-label),Status epilepticus (off-label)
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Hepatic via CYP2B6 and CYP3A4; major metabolite norketamine.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Approximately 47% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 5–10% bound to plasma proteins (primarily albumin).
Volume of distribution is 3–5 L/kg, indicating extensive tissue distribution and accumulation in lipid-rich tissues (e.g., brain, adipose).
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
Oral: 17–20% (extensive first-pass metabolism); Intranasal: 45–50%; IM: 93%; Rectal: 25–50%; IV: 100%.
Inhalation: ~100% bioavailable into systemic circulation via lungs.
No specific GFR-based dose adjustment is required. Use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of active metabolite norketamine; monitor for prolonged effects.
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% and titrate to effect. Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose by 50-75% and monitor closely.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Induction: 1-2 mg/kg IV, 3-4 mg/kg IM. Maintenance: 0.5-1 mg/kg IV or IM as needed. Procedural sedation: 0.5-1 mg/kg IV, may repeat. Continuous infusion: 0.2-0.5 mg/kg/h. Maximum single dose: 2 mg/kg IV, 4 mg/kg IM.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Reduce initial dose by 20-50% due to decreased clearance and increased sensitivity. Titrate slowly to effect. Monitor for cardiovascular and cognitive adverse effects closely.
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
None.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
Emergence reactions (hallucinations, confusion),Hemodynamic instability (hypertension, tachycardia),Increased intracranial pressure,Respiratory depression,Urinary tract toxicity with chronic use
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Hypersensitivity to ketamine,Conditions where elevated blood pressure is dangerous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure (relative)
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
No significant food interactions; grapefruit juice may increase ketamine levels via CYP3A4 inhibition, but clinical relevance is unclear; avoid alcohol consumption due to additive sedative effects.
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use only for indicated procedures (e.g., surgical anesthesia, procedural sedation) as maternal hypoxia may risk fetus; potential for neonatal respiratory depression if used near delivery. Neonatal effects: Possible altered neurodevelopment; consider risk-benefit.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
Ketamine enters breast milk; milk-to-plasma ratio approximately 0.8-1.5. Limited data; low absolute dose (<2% maternal weight-adjusted dose). Caution with repeated high doses; monitor infant for sedation, feeding difficulties. American Academy of Pediatrics: compatible with breastfeeding after single doses.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
Pregnancy may alter pharmacokinetics: increased volume of distribution may require higher initial doses; decreased plasma protein binding may increase free fraction. However, standard dosing guidelines for procedures apply; titrate to effect. Use lowest effective dose due to potential neurotoxicity. Caution with repeated use or long infusions.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
Ketamine produces dissociative anesthesia with preserved airway reflexes and respiratory drive at sub-anesthetic doses; monitor for emergence reactions (hallucinations, delirium) especially in adults; co-administer a benzodiazepine to reduce psychotomimetic effects; use with caution in patients with hypertension, tachycardia, or increased intracranial pressure; can cause increased secretions, consider an anticholinergic like glycopyrrolate; analgesic doses are sub-dissociative (0.1-0.5 mg/kg IV); contraindicated in patients with severe coronary artery disease or recent cerebrovascular accident.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
You may feel detached from your body or have unusual dreams during recovery; this is normal and temporary.,Do not drive or operate machinery for 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for at least 24 hours after treatment.,Report any hallucinations, confusion, or difficulty breathing to your healthcare provider immediately.,For nasal spray (esketamine), follow instructions for administration and avoid eating or drinking for 30 minutes after use.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HYDROCHLORIDE vs DESFLURANE, answered by our medical review team.
KETAMINE HYDROCHLORIDE is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HYDROCHLORIDE and DESFLURANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HYDROCHLORIDE is: Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.. The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining KETAMINE HYDROCHLORIDE and DESFLURANE. The risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. KETAMINE HYDROCHLORIDE is classified as Category C. Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use on. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.